Track BBNX and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Beta Bionics, Inc. Common Stock
11 Hughes, Irvine, CA, United States, 92618
IPO
2025
Employees
420
Industry
Medical Devices
Sector
Healthcare
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20268-8
0
Q4 20259-9
0
Q3 20253-3
0
3-quarter cumulative
20 sells0 buys
Analyst Ratings
3 analysts covering
Hold67%recommend hold
Buy
1
Hold
2
Sell
0